Computer-aided detection (CAD) and radiation therapy firm iCAD is reporting growth in demand for its Xoft Axxent electronic brachytherapy system.
In addition, the company updated clinical news regarding Xoft Axxent for the treatment of early-stage breast cancer and nonmelanoma skin cancer.
Some of the latest medical centers to adopt the Xoft system include City of Hope in Duarte, CA; Staten Island University Hospital in New York; Strimling Dermatology, Laser & Vein Institute in Las Vegas; Mobile Skin Cancer Radiation Specialists in Phoenix; and University of Oklahoma Breast Institute in Oklahoma City.
The company noted that 19 U.S. medical centers have enrolled more than 180 patients in a prospective clinical trial to assess the safety, efficacy, and cosmetic outcomes associated with intraoperative radiation therapy (IORT) for early-stage breast cancer with the Xoft system.
According to iCAD, clinical outcomes data on patients with nonmelanoma skin cancer treated with the Xoft system show "acceptable toxicity" with no recurrences at up to three years post-treatment.
Results were presented by Dr. Ajay Bhatnagar, adjunct assistant professor of radiation oncology at the University of Pittsburgh School of Medicine and chief medical officer at DermEbx, at the American Society for Radiation Oncology (ASTRO) annual meeting.
